Joshua Thomas, MD
Hematology & Oncology · Dallas, TXNPI 1982264164
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 111 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$483
- Johnson & Johnson$412
- Sanofi$255
- Merck$192
- Karyopharm Therapeutics Inc.$145
- Rigel Pharmaceuticals, Inc.$142
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,73894%
- Education$1706%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 19 | $483 |
| Johnson & Johnson | 7 | $412 |
| Sanofi | 8 | $255 |
| Merck | 7 | $192 |
| Karyopharm Therapeutics Inc. | 7 | $145 |
| Rigel Pharmaceuticals, Inc. | 9 | $142 |
| Blueprint Medicines Corporation | 6 | $138 |
| Morphosys, US Inc. | 4 | $85 |
| GSK | 3 | $75 |
| Lilly USA, LLC | 1 | $75 |
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| AstraZeneca | 3 | $70 |
| Seagen Inc. | 3 | $65 |
| Regeneron Healthcare Solutions, Inc. | 2 | $64 |
| Genmab U.S., Inc. | 3 | $60 |
| AbbVie | 2 | $51 |
| Adaptive Biotechnologies Corporation | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Sobi, Inc | 2 | $43 |
| Syndax Pharmaceuticals, Inc. | 2 | $42 |
| Mirati Therapeutics, Inc. | 2 | $39 |
| Acrotech Biopharma Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Accord Healthcare, Inc. | 1 | $28 |
| Pfizer | 1 | $27 |
| Geron Corporation | 1 | $25 |
| Bayer | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Epizyme, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,908 in reported general payments places this provider in the 45th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.